All
Companion Website for “The Story of Cancer†Documentary Launches as Part of a National Outreach
May 27th 2014WETA, the Washington, DC, public television station, has launched a new website as part of a national outreach for the documentary The Story of Cancer: The Emperor of All Maladies, which will be produced by Ken Burns.
Panitumumab Gains FDA Approval for KRAS Wild-Type mCRC
May 24th 2014The FDA has approved panitumumab (Vectibix) in combination with chemotherapy as a frontline treatment for patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC), based on findings from two phase III clinical trials.
FDA Grants Breakthrough Therapy Designation for CO-1686 for EGFR T790M-Positive NSCLC
May 21st 2014The EGFR inhibitor CO-1686 has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic T790M mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of EGFR-targeted therapy.
Vemurafenib/ Cobimetinib Combination Demonstrates Efficacy in Melanoma
May 9th 2014The combination of vemurafenib with the investigational MEK inhibitor cobimetinib demonstrated a 13.7-month median PFS and an ORR of 87% in treatment-naïve patients with BRAFV600 mutation-positive metastatic melanoma.
Demcizumab Receives Orphan Drug Designation for Pancreatic Cancer
May 6th 2014The FDA Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18), which is currently in a phase Ib clinical trial in combination with Abraxane® (nab-paclitaxel) and gemcitabine.
Ramucirumab Approved by FDA for Gastric and GEJ Adenocarcinoma
April 22nd 2014The FDA has approved ramucirumab as a treatment for patients with unresectable gastric cancer or GEJ adenocarcinoma following fluoropyrimidine- or platinum-containing therapy, based on a significant extension in overall survival (OS).
First-Line Ofatumumab Approved by FDA for Chemotherapy-Ineligible Patients With CLL
April 18th 2014The FDA has approved ofatumumab (Azerra) plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia (CLL) who are considered inappropriate for treatment with fludarabine therapy.
Neratinib Shows Promise for HER2-Positive Breast Cancer in I-SPY 2 Trial
April 10th 2014The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer.